{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:43:27Z","timestamp":1790246607929,"version":"4.1.0"},"reference-count":31,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2007,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>MenBvac and MeNZB are safe and efficacious vaccines against serogroup B meningococcal disease. MenBvac is prepared from a B:15:P1.7,16 meningococcal strain (strain 44\/76), and MeNZB is prepared from a B:4:P1.7-2,4 strain (strain NZ98\/254). At 6-week intervals, healthy adults received three doses of MenBvac (25 \u03bcg), MeNZB (25 \u03bcg), or the MenBvac and MeNZB (doses of 12.5 \u03bcg of each vaccine) vaccines combined, followed by a booster 1 year later. Two-thirds of the subjects who received a monovalent vaccine in the primary schedule received the other monovalent vaccine as a booster dose. The immune responses to the combined vaccine were of the same magnitude as the homologous responses to each individual vaccine observed. At 6 weeks after the third dose, 77% and 87% of the subjects in the combined vaccine group achieved serum bactericidal titers of \u22654 against strains 44\/76 and NZ98\/254, respectively, and 97% and 93% of the subjects achieved a fourfold or greater increase in opsonophagocytic activity against strains 44\/76 and NZ98\/254, respectively. For both strains, a trend of higher responses after the booster dose was observed in all groups receiving at least one dose of the respective strain-specific vaccine. Local and systemic reactions were common in all vaccine groups. Most reactions were mild or moderate in intensity, and there were no vaccine-related serious adverse events. The safety profile of the combined vaccine was not different from those of the separate monovalent vaccines. In conclusion, use of either of the single vaccines or the combination of MenBvac and MeNZB may have a considerable impact on the serogroup B meningococcal disease situation in many countries.<\/jats:p>","DOI":"10.1128\/cvi.00094-07","type":"journal-article","created":{"date-parts":[[2007,7,19]],"date-time":"2007-07-19T01:31:13Z","timestamp":1184808673000},"page":"1062-1069","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":47,"title":["Immunogenicity and Safety of a Combination of Two Serogroup B Meningococcal Outer Membrane Vesicle Vaccines"],"prefix":"10.1128","volume":"14","author":[{"given":"Synne","family":"Sandbu","sequence":"first","affiliation":[{"name":"Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway"},{"name":"Novartis Vaccines and Diagnostics S.r.l., Siena, Italy"},{"name":"Novartis Vaccines BCDM, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berit","family":"Feiring","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway"},{"name":"Novartis Vaccines and Diagnostics S.r.l., Siena, Italy"},{"name":"Novartis Vaccines BCDM, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Oster","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway"},{"name":"Novartis Vaccines and Diagnostics S.r.l., Siena, Italy"},{"name":"Novartis Vaccines BCDM, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oddveig S.","family":"Helland","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway"},{"name":"Novartis Vaccines and Diagnostics S.r.l., Siena, Italy"},{"name":"Novartis Vaccines BCDM, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde S. W.","family":"Bakke","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway"},{"name":"Novartis Vaccines and Diagnostics S.r.l., Siena, Italy"},{"name":"Novartis Vaccines BCDM, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisbeth M.","family":"N\u00e6ss","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway"},{"name":"Novartis Vaccines and Diagnostics S.r.l., Siena, Italy"},{"name":"Novartis Vaccines BCDM, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audun","family":"Aase","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway"},{"name":"Novartis Vaccines and Diagnostics S.r.l., Siena, Italy"},{"name":"Novartis Vaccines BCDM, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingeborg S.","family":"Aaberge","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway"},{"name":"Novartis Vaccines and Diagnostics S.r.l., Siena, Italy"},{"name":"Novartis Vaccines BCDM, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Cathrine","family":"Kristoffersen","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway"},{"name":"Novartis Vaccines and Diagnostics S.r.l., Siena, Italy"},{"name":"Novartis Vaccines BCDM, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjersti M.","family":"Rydland","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway"},{"name":"Novartis Vaccines and Diagnostics S.r.l., Siena, Italy"},{"name":"Novartis Vaccines BCDM, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Tilman","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway"},{"name":"Novartis Vaccines and Diagnostics S.r.l., Siena, Italy"},{"name":"Novartis Vaccines BCDM, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne","family":"N\u00f8kleby","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway"},{"name":"Novartis Vaccines and Diagnostics S.r.l., Siena, Italy"},{"name":"Novartis Vaccines BCDM, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar","family":"Rosenqvist","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway"},{"name":"Novartis Vaccines and Diagnostics S.r.l., Siena, Italy"},{"name":"Novartis Vaccines BCDM, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/S0264-410X(02)00774-0","volume":"21","year":"2003","unstructured":"Aase, A., L. M. Naess, R. H. Sandin, T. K. Herstad, F. Oftung, J. Holst, I. L. Haugen, E. A. H\u00f8iby, and T. E. Michaelsen. 2003. Comparison of functional immune responses in humans after intranasal and intramuscular immunisations with outer membrane vesicle vaccines against group B meningococcal disease. Vaccine21:2042-2051.","journal-title":"Vaccine"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/0140-6736(91)91961-S","volume":"338","year":"1991","unstructured":"Bjune, G., E. A. H\u00f8iby, J. K. Gr\u00f8nnesby, O. Arnesen, J. H. Fredriksen, A. Halstensen, E. Holten, A. K. Lindbak, H. N\u00f8kleby, and E. Rosenqvist. 1991. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet338:1093-1096.","journal-title":"Lancet"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1128\/CDLI.12.8.970-976.2005","volume":"12","year":"2005","unstructured":"Borrow, R., I. S. Aaberge, G. F. Santos, T. L. Eudey, P. Oster, A. Glennie, J. Findlow, E. A. H\u00f8iby, E. Rosenqvist, P. Balmer, and D. Martin. 2005. Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup B, strain 44\/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin. Diagn. Lab. Immunol.12:970-976.","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","volume":"23","year":"2005","unstructured":"Borrow, R., P. Balmer, and E. Miller. 2005. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine23:2222-2227.","journal-title":"Vaccine"},{"key":"e_1_3_2_6_2","first-page":"65","volume":"4","year":"2006","unstructured":"Boutriau, D., J. Poolman, R. Borrow, J. Findlow, J. Diez Domingo, J. Puig-Barbera, J. M. Baldo, V. Planelles, A. Jubert, J. Colomer, A. Gil, K. Levie, A. D. Kervyn, V. Weynants, F. Dominguez, R. Barbera, and F. Sotolongo. 2006. Immunogenicity and safety of three doses of a bivalent (B:4:P1.19,15 and B:4:P1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents. Clin. Vaccine Immunol.4:65-73.","journal-title":"Clin. Vaccine Immunol."},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0264-410X(01)00371-1","volume":"20","year":"2001","unstructured":"de Kleijn, E., L. van Eijndhoven, C. Vermont, B. Kuipers, H. van Dijken, H. Rumke, R. de Groot, L. van Alphen, and G. van den Dobbelsteen. 2001. Serum bactericidal activity and isotype distribution of antibodies in toddlers and schoolchildren after vaccination with RIVM hexavalent PorA vesicle vaccine. Vaccine20:352-358.","journal-title":"Vaccine"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1016\/j.vaccine.2005.01.050","volume":"23","year":"2005","unstructured":"Dyet, K., A. Devoy, R. McDowell, and D. Martin. 2005. New Zealand's epidemic of meningococcal disease described using molecular analysis: implications for vaccine delivery. Vaccine23:2228-2230.","journal-title":"Vaccine"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00047-06"},{"key":"e_1_3_2_10_2","unstructured":"Methods in molecular medicine 2001 vol. 66"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0264-410X(02)00591-1","volume":"21","year":"2003","unstructured":"Holst, J., B. Feiring, J. E. Fuglesang, E. A. H\u00f8iby, H. N\u00f8kleby, I. S. Aaberge, and E. Rosenqvist. 2003. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine21:734-737.","journal-title":"Vaccine"},{"key":"e_1_3_2_12_2","unstructured":"A \u2018tailor made\u2019 vaccine trialled as part of public health response to group B meningococcal epidemic in New Zealand. 2003"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.vaccine.2005.10.003","volume":"24","year":"2006","unstructured":"Luijkx, T., H. van Dijken, C. van Els, and G. van den Dobbelsteen. 2006. Heterologous prime-boost strategy to overcome weak immunogenicity of two serosubtypes in hexavalent Neisseria meningitidis outer membrane vesicle vaccine. Vaccine24:1569-1577.","journal-title":"Vaccine"},{"key":"e_1_3_2_14_2","first-page":"331","volume":"66","year":"2001","unstructured":"Michaelsen, T. E., and A. Aase. 2001. Antibody-induced opsonophagocytosis of serogroup B meningococci measured by flow cytometry, p. 331-337. In A. J. Pollard and M. C. J. Maiden (ed.), Methods in molecular medicine, vol. 66. Meningococcal vaccines. Humana Press, Totowa, NJ.","journal-title":"Methods in molecular medicine"},{"key":"e_1_3_2_15_2","unstructured":"Meningococcal B Immunisation Programme effectiveness shown. 2006"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.70.11.6021-6031.2002"},{"key":"e_1_3_2_17_2","first-page":"284","year":"2002","unstructured":"N\u00e6ss, L. M., T. Torill, A.-C. Kristoffersen, I. S. Aaberge, E. A. H\u00f8iby, and E. Rosenqvist. 2002. Immunogenicity of a combination of two different outer membrane protein based meningococcal group B vaccines, p. 284. In D. A. Caugant and E. Wedege (ed.), Abstr. 13th Int. Pathogenic Neisseria Conf., Oslo 2002. Nordberg Aksidenstrykkeri AS, Oslo, Norway.","journal-title":"Abstr. 13th Int. Pathogenic Neisseria Conf."},{"key":"e_1_3_2_18_2","unstructured":"Surveillance of bacterial meningitis in Europe 1999\/2000. 2002"},{"key":"e_1_3_2_19_2","first-page":"95","volume":"14","year":"1991","unstructured":"N\u00f8kleby, H., and B. Feiring. 1991. The Norwegian meningococcal group B outer membrane vesicle vaccine: side effects in phase II trials. NIPH Ann.14:95-102.","journal-title":"NIPH Ann."},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1016\/j.vaccine.2007.01.022","volume":"25","year":"2007","unstructured":"N\u00f8kleby, H., P. Aavitsland, J. O'Hallahan, B. Feiring, S. Tilman, and P. Oster. 2007. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease. Vaccine25:3080-3084.","journal-title":"Vaccine"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/j.vaccine.2005.01.063","volume":"23","year":"2005","unstructured":"Oster, P., D. Lennon, J. O'Hallahan, K. Mulholland, S. Reid, and D. Martin. 2005. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine23:2191-2196.","journal-title":"Vaccine"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1016\/j.vaccine.2007.01.023","volume":"25","year":"2007","unstructured":"Oster, P., J. O'Hallahan, I. Aaberge, S. Tilman, E. Ypma, and D. Martin. 2007. Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand. Vaccine25:3075-3079.","journal-title":"Vaccine"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.63.12.4642-4652.1995"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1093\/infdis\/155.6.1266","volume":"155","year":"1987","unstructured":"Ross, S. C., P. Rosenthal, H. M. Berberich, and P. Densen. 1987. Killing of Neisseria meningitidis by human neutrophils: implications for normal and complement-deficient individuals. J. Infect. Dis.155:1266-1275.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_25_2","first-page":"U1015","volume":"117","year":"2004","unstructured":"Sexton, K., D. Lennon, P. Oster, S. Crengle, D. Martin, K. Mulholland, et al. 2004. The New Zealand meningococcal vaccine strategy: a tailor-made vaccine to combat a devastating epidemic. N. Z. Med. J.117:U1015.","journal-title":"N. Z. Med. J."},{"key":"e_1_3_2_26_2","first-page":"195","volume":"14","year":"1991","unstructured":"Sierra, G. V., H. C. Campa, N. M. Varcacel, I. L. Garcia, P. L. Izquierdo, P. F. Sotolongo, G. V. Casanueva, C. O. Rico, C. R. Rodriguez, and M. H. Terry. 1991. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann.14:195-207.","journal-title":"NIPH Ann."},{"key":"e_1_3_2_27_2","first-page":"1520","volume":"281","year":"1999","unstructured":"Tappero, J. W., R. Lagos, A. M. Ballesteros, B. Plikaytis, D. Williams, J. Dykes, L. L. Gheesling, G. M. Carlone, E. A. H\u00f8iby, J. Holst, H. N\u00f8kleby, E. Rosenqvist, G. Sierra, C. Campa, F. Sotolongo, J. Vega, J. Garcia, P. Herrera, J. T. Poolman, and B. A. Perkins. 1999. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines. A randomized controlled trial in Chile. JAMA281:1520-1527.","journal-title":"JAMA"},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.vaccine.2005.09.043","volume":"24","year":"2006","unstructured":"Thornton, V., D. Lennon, K. Rasanathan, J. O'Hallahan, P. Oster, J. Stewart, S. Tilman, I. Aaberge, B. Feiring, and H. N\u00f8kleby. 2006. Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control. Vaccine24:1395-1400.","journal-title":"Vaccine"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.74.5.2803-2808.2006"},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.ijantimicag.2006.11.031","volume":"29","year":"2007","unstructured":"Tzanakaki, G., and P. Mastrantonio. 2007. Aetiology of bacterial meningitis and resistance to antibiotics of causative pathogens in Europe and in the Mediterranean region. Int. J. Antimicrob. Agents29:621-629.","journal-title":"Int. J. Antimicrob. Agents"},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1016\/j.vaccine.2006.09.025","volume":"25","year":"2007","unstructured":"van den Dobbelsteen, G. P., H. H. van Dijken, S. Pillai, and L. van Alphen. 2007. Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs. Vaccine25:2491-2496.","journal-title":"Vaccine"},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/infdis\/126.5.514","volume":"126","year":"1972","unstructured":"Wyle, F. A., M. S. Artenstein, B. L. Brandt, E. C. Tramont, D. L. Kasper, P. L. Altieri, S. L. Berman, and J. P. Lowenthal. 1972. Immunologic response of man to group B meningococcal polysaccharide vaccines. J. Infect. Dis.126:514-522.","journal-title":"J. Infect. Dis."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00094-07","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00094-07","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:38:50Z","timestamp":1627591130000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00094-07"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["10.1128\/CVI.00094-07"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00094-07","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9]]},"assertion":[{"value":"2007-02-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2007-07-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}